乳腺癌患者术后辅助治疗的临床效果及其影响因素分析

doi:10.13481/j.1671-587x.20150338

摘要/Abstract

摘要：

目的:分析476例乳腺癌术后辅助治疗患者的病理、临床资料及预后情况,探讨影响乳腺癌预后的相关因素。方法:随访2007—2010年本院乳腺癌术后病理分期为Ⅰ~Ⅲ期且行辅助治疗的患者476例,中位随访时间为50.5个月,采用Kaplan- Meier法绘制生存曲线,Log-rank检验进行生存率差异比较,采用COX比例风险回归模型进行单因素及多因素分析,了解影响乳腺癌预后的相关危险因素。结果:患者3年无病生存率为94.3%。单因素分析,年龄、肿瘤大小、淋巴结转移数目、脉管癌栓、激素受体状态、HER-2表达情况和分子分型是影响无病生存期(DFS)的因素(P<0.05);其中年龄越小、肿瘤越大、淋巴结转移越多、脉管癌栓越多、激素受体阳性率越低、HER-2表达扩增和分子分型是HER-2过表达型及基底样型,DFS越短。多因素分析,激素受体状态和HER-2表达情况是影响DFS的独立因素(P<0.05)。3年总生存率为97.6%。单因素分析,肿瘤大小、淋巴结转移情况、脉管癌栓、激素受体状态和HER-2表达情况是影响乳腺癌总生存期(OS)的因素(P<0.05);其中肿瘤越大、淋巴结转移越多、脉管癌栓越多、激素受体阳性率越小和HER-2表达扩增,OS越短;多因素分析,淋巴结转移数目、激素受体状态和HER-2表达情况是影响OS的独立因素(P<0.05)。结论:淋巴结转移数目、激素受体状态和HER-2表达情况是乳腺癌术后辅助治疗疗效的影响因素,与预后有密切关联。

关键词: 乳腺肿瘤, 辅助治疗, 生存率, 预后

Abstract:

Objective To analyze the clinical pathologic characteristics, treatment and prognosis of 476 breast cancer patients, and to explore the related factors influencing the prognosis of breast cancer. Methods 476 breast cancer patients received postoperative adjuvant therapy were followed up who were diagnosed as the pathologic stage Ⅰ-Ⅲ from 2007 to 2010.The median follow-up time was 50.5 months.Kaplan-Meier method was used to draw the survival curve, and Log-rank test was used to compare the survival rates;COX proportional hazards model was used to analyze single factors and multiple factors.The risk factors related to the prognosis of breast cancer were analyzed. Results The 3-year disease free survival rate of the patients was 94.3%.The single factor analysis showed that age, tumor size, the number of metastatic lymph nodes, vascular tumor emboli, hormone receptor status, HER-2 expression and molecular subtypes were the influencing factors of disease free survival(DFS) (P<0.05).The smaller age, the larger neoplasm, the more metastatic lymph nodes, the more vascular tumor emboli, the lower positive rate of hormone receptor, the over-expression of HER-2, the molecular subtypes of HER-2 over-expression and the basal-like subtype had poor prognosis among them.The multifactor analysis demonstrated that hormone receptor status and HER-2 expression were independent factors influencing DFS (P<0.05).The 3-year overall rate of the patients was 97.6%.The single factor analysis showed that the tumor size, the number of metastatic lymph nodes, vascular tumor emboli, hormone receptor status and HER-2 expression were the influencing factors of overall survival (OS)(P<0.05).The multiple factor analysis demonstrated the number of metastatic lymph node, hormone receptor status and HER-2 expression were independent factors of OS (P<0.05). Conclusion The number of metastatic lymph nodes, hormone receptor status and HER-2 expression are significantly independent indicators of prognosis in the patients with breast cancer respectively.

Key words: breast neoplasms, adjuvant therapy, survival rate, prognostis

中图分类号:

R734.2

董营, 康丽花, 关萌, 吕铮, 宋艳秋. 乳腺癌患者术后辅助治疗的临床效果及其影响因素分析[J]. 吉林大学学报(医学版), 2015, 41(03): 636-642.

DONG Ying, KANG Lihua, GUAN Meng, LYU Zheng, SONG Yanqiu. Clinical effect and influencing factor analysis of postoperative adjuvant therapy for patients with breast cancer[J]. Journal of Jilin University Medicine Edition, 2015, 41(03): 636-642.

参考文献

[1] Zheng G, Peng F, Ding R, et al.Identification of proteins responsible for the multiple drug resistance in 5-fluorouracil-induced breast cancer cell using proteomics analysis[J].Cancer Res Clin Oncol, 2010, 136(10):1477-1488.

[2] 中国抗癌协会.乳腺癌诊治指南与规范(2007 版) [J].中国癌症杂志, 2007, 17(5):412-413.

[3] 吴清然.中国女性乳腺癌危险因素的系统评价[J].现代预防医学, 2011, 38(1):61-72.

[4] 史建军, 刘涛, 李珂, 等.110例青年女性乳腺癌预后分析[J].中国妇幼保健, 2014, 29(9):1348-1350.

[5] Goldhirsch A, Glick JH, Gelber RD, et al.Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005[J].Ann Oncol, 2005, 16(10):1569-1583.

[6] Goldhirsch A, Wood WC, Gelber RD, et al.Progress and promise:highlights of the international expert consensus on the primary therapy of early breast cancer 2007[J].Ann Oncol, 2007, 18(7): 1133-1144.

[7] Barni S, Venturini M, Molino A, et al.Importance of adherence to guidelines in breast cancer clinical practice. The Italian experience (AIOM) [J].Tumori, 2011, 97(5):559-563.

[8] Han W, Kang SY.Relationship between age at diagnosis and outcome of Premenopausal breast cancer:age less than 35 years is a reasonable cut off for defining young age-onset breast cancer[J].Breast Cancer Res Treat, 2010, 119(1): 193-200.

[9] De la Rochefordiere A, Asselain B, Campana F, et al.Age as prognostic factor in premenopausal breast carcinoma[J].Lancet, 1993, 341(8852):1039-1043.

[10] Martin M, Pienkowski T, Mackey J, et al.Adjuvant docetaxel for node-positive breast cancer[J].N Engl J Med, 2005, 352(22):2302-2313.

[11] Khanfir A, Frikha M, Kallel F, et al.Breast cancer in young women in the south of Tunisia[J].Cancer Radiother, 2006, 10(8):565-571.

[12] 黄波.COX比例风险模型分析乳腺癌的预后[J].当代医学, 2009, 15(10):76-77.

[13] Bonadonna G, Moliterni A, Zambetti M, et al.30 years'follow up of randomized studies of adjuvant CMF in operable breast cancer:cohort study[J].BMJ, 2005, 330(7485):217-220.

[14] Kim IK, Park S, Hwang H, et al.Clinical significance of age at the time of diagnosis among young breast cancer patients[J].J Breast Cancer, 2011, 14(4):314-321.

[15] 秦颖, 张同先, 张巍, 等.青年乳腺癌临床病理特点分子分型及预后分析[J].中国肿瘤临床, 2014, 41(4):231-236.

[16] 张继运, 刘雨雄, 沙新海, 等.青年老年乳腺癌临床病理资料与预后的探讨[J].中华乳腺病杂志:电子版, 2012, 6(3):259-263.

[17] 周灿, 王珂, 何建军, 等.不同年龄段女性乳腺癌患者临床病理特征的回顾性分析[J].西安交通大学学报:医学版, 2013, 34(1):133-137.

[18] 王珂, 周灿, 谢四梅, 等.患者职业对乳腺癌临床病理特征及治疗模式的影响[J].西安交通大学学报:医学版, 2013, 34(2):218-223.

[19] 庄秀芬, 张幸平, 郭慧琳, 等.107 例乳腺癌患者综合治疗的疗效及预后分析[J].重庆医科大学学报, 2010, 35(1):130-134.

[20] 何建苗, 马小军, 赵华洲, 等.术前置泵区域动脉灌注化疗治疗晚期乳腺癌远期疗效分析[J].解放军医学杂志, 2014, 39(10):831-833.

[21] 武萍萍, 陶然, 彭攸, 等.EZH2及DNMT1在三阴性乳腺癌中的表达及意义[J].解放军医学杂志, 2015, 40(1):50-55.

[22] Berry D, Cirrineion C, Henderson I, et al.Estrogen-receptor status and outcome of modern chemotherapy for patients with node-positive breast cancer[J].JAMA, 2006, 295(14):1658-1667.

[23] Inic Z, Zegarac M, Inic M, et al.Difference between luminal A and luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information[J].Clin Med Insights Oncol, 2014, 11(8):107-111.

[24] 陈崇, 周桃玉, 温旺荣.乳腺癌组织中 Ki-67表达及其临床意义的Meta分析[J].肿瘤学杂志, 2014(4):270-275.

[25] Gong P, Wang Y, Liu G, et al.New insight into Ki67 expression at the invasive front in breast cancer[J].PLoS One, 2013, 8(1):e54912.